Evidence map›Paper›PMID 42080322›Full record

ArticlemAbs2026

Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody.

Laura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, Tim Delahaye, Emma K Persson, Christophe Blanchetot, Hans de Haard, C Erik Hack, Gregers Rom Andersen, Inge Van de Walle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laura Brackeargenx BVBA, Zwijnaarde, Belgium.ORCID 0009-0002-0221-9359
Heidi Gytz OlesenDepartment of Molecular Biology and Genetics - Protein Science, Aarhus University, Aarhus C, Denmark.ORCID 0000-0003-4870-9214
Erwin Pannecouckeargenx BVBA, Zwijnaarde, Belgium.ORCID 0000-0003-3014-1851
Tim Delahayeargenx BVBA, Zwijnaarde, Belgium.ORCID 0009-0005-0594-7660
Emma K Perssonargenx BVBA, Zwijnaarde, Belgium.ORCID 0000-0002-9874-7991
Christophe Blanchetotargenx BVBA, Zwijnaarde, Belgium.ORCID 0000-0001-9152-9978
Hans de Haardargenx BVBA, Zwijnaarde, Belgium.
C Erik Hackargenx BVBA, Zwijnaarde, Belgium.
Gregers Rom AndersenDepartment of Molecular Biology and Genetics - Protein Science, Aarhus University, Aarhus C, Denmark.ORCID 0000-0001-6292-3319
Inge Van de Walleargenx BVBA, Zwijnaarde, Belgium.ORCID 0000-0002-7631-399X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Empasiprubart (ARGX-117) is a humanized recycling antibody that prevents binding of C2 to C4b, blocking downstream classical and lectin pathways of complement activation. Empasiprubart binds to the CCP2 domain of complement component C2 in a calcium- and pH-dependent manner, leveraging physiological differences between blood and endosomal environments to facilitate the release and subsequent degradation of bound C2. The molecule incorporates Fc region mutations (H433K and N434F) that enhance its affinity for the neonatal Fc receptor (FcRn) under acidic endosomal conditions, thereby prolonging its

Indexed as

CalciumCrystallography, X-RayHumansHydrogen-Ion ConcentrationReceptors, FcStructure-Activity RelationshipCalciumReceptors, FcAntibodyCa2+-dependencycomplementhistidinepH-dependencystructure

Identifiers

PMID42080322
PMCPMC13154994

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.